Literature DB >> 7858871

The effect of non-steroidal anti-inflammatory drugs on the accumulation and release of interleukin-1-like activity by peritoneal macrophages from the mouse.

A K Bahl1, M M Dale, J C Foreman.   

Abstract

1. The non-steroidal anti-inflammatory drugs (NSAIDs) indomethacin, 10 and 100 microM, piroxicam, 100 microM, and sodium meclofenamate, 1 and 100 microM, potentiated the lipopolysaccharide (LPS)-stimulated release of interleukin-1 (IL-1)-like activity from mouse peritoneal macrophages. Aspirin up to 100 microM was without effect. The drugs did not themselves stimulate the release of IL-1-like activity at the concentrations used. 2. LPS, 1 microgram ml-1, stimulated prostaglandin E2 production by mouse peritoneal macrophages and this was totally inhibited by aspirin, 100 microM, indomethacin, 1 microM, piroxicam, 10 microM and sodium meclofenamate, 0.1 microM. 3. The potentiation of LPS-stimulated release of IL-1-like activity produced by indomethacin, 100 microM, piroxicam, 100 microM, or sodium meclofenamate, 10 microM, was inhibited by prostaglandin E2, (PGE2) 10 ng ml-1. 4. Aspirin, 100 microM, indomethacin, 100 nM to 10 microM, piroxicam, 1 to 100 microM, and sodium meclofenamate, 10 nM, all potentiated cell-associated IL-1-like activity in LPS- stimulated macrophages. The drugs had no effect on cell-associated IL-1-like activity by themselves. 5. Exogenous PGE2, 2 to 30 ng ml-1, inhibited the cell-accumulation of IL-1-like activity stimulated by LPS in the presence of indomethacin, 1 microM, or sodium meclofenamate, 0.1 microM. 6. The 5-lipoxygenase inhibitors BWA4C, 0.01 to 10 microM, and L-651,392, 0.01 to 10 microM, had no effect on LPS-stimulated released or cell-associated IL-1-like activity. Over the same concentration-ranges,neither of the 5-lipoxygenase inhibitors affected released or cell-associated IL-1-like activity in LPS stimulated mouse macrophages in the presence of indomethacin, 1 JM.7. The synthetic diacylglycerol, DiC8, 10 to 200 JAM, did not itself increase released or cell-associated IL-I-like activity but in the presence of the diacylglycerol kinase inhibitor, R59022, 10 JM, DiC8increased released and cell-associated IL-i-like activity. The activity of DiC8 on released and cell associated IL-l-like activity was not increased by indomethacin, 100 micro M.8. NSAIDs increase LPS-induced cell-associated IL-i-like activity in mouse macrophages by inhibiting the formation of cyclo-oxygenase products such as PGE2 but at higher concentrations the NSAIDs potentiate LPS-induced release of IL-I-like activity by a mechanism independent of cyclo-oxygenase inhibition. The potentiation of the release of IL-i-like activity appears not to be related to an effect of NSAIDs on either 5-lipoxygenase or diacylglycerol metabolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858871      PMCID: PMC1510457          DOI: 10.1111/j.1476-5381.1994.tb17065.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Comparison of the effects of indomethacin, RHC80267 and R59022 on superoxide production by 1,oleoyl-2,acetyl glycerol and A23187 in human neutrophils.

Authors:  M M Dale; A Penfield
Journal:  Br J Pharmacol       Date:  1987-09       Impact factor: 8.739

2.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

3.  Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid.

Authors:  H W Emori; G D Champion; R Bluestone; H E Paulus
Journal:  Ann Rheum Dis       Date:  1973-09       Impact factor: 19.103

4.  Conditions required for expression of membrane IL 1 on B cells.

Authors:  E A Kurt-Jones; J M Kiely; E R Unanue
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

5.  Acetabular bone destruction related to non-steroidal anti-inflammatory drugs.

Authors:  N M Newman; R S Ling
Journal:  Lancet       Date:  1985-07-06       Impact factor: 79.321

6.  [Evaluation of the effect of analgesics/antiphlogistics on the progression of spontaneous arthrosis in the C57 black mouse].

Authors:  R Maier; G Wilhelmi
Journal:  Z Rheumatol       Date:  1983 Jul-Aug       Impact factor: 1.372

7.  Prostaglandin E2 rather than lymphocyte-activating factor produced by activated human mononuclear cells stimulates increases in murine thymocyte cAMP.

Authors:  J J Oppenheim; W J Koopman; L M Wahl; S F Dougherty
Journal:  Cell Immunol       Date:  1980-01       Impact factor: 4.868

8.  Relative activities of rat and dog platelet phospholipase A2 and diglyceride lipase. Selective inhibition of diglyceride lipase by RHC 80267.

Authors:  C A Sutherland; D Amin
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

9.  The inhibitory effects of steroidal and non-steroidal antirheumatic drugs on articular cartilage in osteoarthrosis and its counteraction by a biological GAG-peptide complex (Rumalon).

Authors:  D A Kalbhen
Journal:  Z Rheumatol       Date:  1982 Sep-Oct       Impact factor: 1.372

10.  Identification of a membrane-associated interleukin 1 in macrophages.

Authors:  E A Kurt-Jones; D I Beller; S B Mizel; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

View more
  2 in total

1.  A comparison of the disease-modifying and cytokine-regulating activities of tenidap, piroxicam and cyclosporin-A using the adjuvant-induced model of arthritis in rats.

Authors:  D R Haynes; M J Hutchens; M W Whitehouse; B Vernon-Roberts
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

2.  Plasma and synovial fluid interleukin-1, interleukin-6 and substance P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal anti inflammatory drugs indomethacin, diclofenac and naproxen.

Authors:  P Sacerdote; M Carrabba; A Galante; R Pisati; B Manfredi; A E Panerai
Journal:  Inflamm Res       Date:  1995-11       Impact factor: 4.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.